The Effects of Dupilumab on Allergic Contact Dermatitis
Phase 4
Active, not recruiting
NCT03935971
| Condition | Allergic Contact Dermatitis |
|---|
| Phase | Phase 4 |
|---|
| Sponsor | Brigham and Women's Hospital |
|---|
| Status | Active, not recruiting |
|---|
| Enrollment | 17 participants |
|---|
| Interventions | Dupilumab |
|---|
| Start date | Dec 18, 2019 |
|---|
| Completion date | Dec 31, 2024 |
|---|
| Results posted | Feb 27, 2026 |
|---|
Summary
The aim of this study is to investigate the effects of dupilumab on allergic contact dermatitis.
Change From Baseline in Investigator's Global Assessment (IGA) Score
week 0, week 6, week 12 · mean IGA scores
| Subjects With Allergic Contact Dermatitis | 3.5 mean IGA scores |
|---|
| Subjects With Allergic Contact Dermatitis | 2 mean IGA scores |
|---|
| Subjects With Allergic Contact Dermatitis | 0.83 mean IGA scores |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.